Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
siriusrna.com is the official website of clinical-stage biotech company Sirius Therapeutics. Founded in 2021, the company operates with dual headquarters in San Diego, US and Shanghai, China, and focuses on developing innovative siRNA (small interfering RNA) therapies for chronic diseases. Its core pipeline targets three areas with unmet clinical needs: coagulation disorders, cardiometabolic diseases, and obesity. Currently, two of its core pipeline candidates have advanced to Phase II clinical trials. The official website supports bilingual switching between Chinese and English, and publicly discloses corporate information, R&D milestones, pipeline progress and latest updates, making information accessible to industry practitioners, investors and partners.
The website fully discloses the company's team background, financing information and pipeline progress: its core candidate SRSD216 targets hyperlipoprotein(a)emia. Phase I clinical data shows it reduces Lp(a) by up to 94.7%, with effects lasting 7 months and a good safety profile. SRSD107, a long-acting FXI inhibitor, has already initiated multiple Phase II clinical trials, and Sirius Therapeutics has entered into a global collaboration with CRISPR Therapeutics for this candidate, with the two parties splitting costs and profits equally. The site has clear navigation that makes it easy to access key information, but there is an issue with duplicate loading for some content, and some secondary pages trigger 404 errors, so the overall structure still has room for optimization.
This website is not a service platform for general consumers, and is mainly intended for researchers in the biopharmaceutical industry, biopharmaceutical investors, and clinical collaboration organizations. Currently, the website is directly accessible to users in China. Its Chinese interface is fully adapted to the needs of domestic users, and all core clinical information has corresponding Chinese content.
Overall, as an emerging startup in the siRNA space, Sirius Therapeutics has standardized, clear information disclosure on its official website, and the potential of its core pipeline deserves industry attention.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on siriusrna.com official site.
siriusrna.com is an United States Health provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach siriusrna.com directly.